UPCC 39418: A Phase II Single Arm Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) In Adult Patients with Refractory or Relapsed Follicular Lymphoma

Enrolling By Invitation
99 years or below
All
Phase 2
10 participants needed

Brief description of study

To evaluate the efficacy of tisagenlecleucel therapy among adult patients with refractory or relapsed follicular lymphoma as measured by complete response rate determined by Independent Review Committee in the full analysis set based on Lugano 2014 classification response criteria.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: lymphoma
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 831805
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

 

Interested in the study?

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact a study center.